KIMS

Q1 performance is a mixed bag

delivered a mixed financial performance in Q1 FY26, with strong revenue growth but a decline in profitability. Despite being a seasonally weak period, the company's revenue increased by 27% year-on-year, fueled by a healthy increase in patient volumes and a higher average revenue per occupied bed (ARPOB). → Performance Indicators: In-patient (IP) and out-patient (OP) volumes grew by 15% and 19% respectively, indicating robust demand for its services. ARPOB increased by 12% year-on-year to ₹43,011, showcasing strong pricing power and a favorable patient mix. → Profitability Challenges: The EBITDA margin contracted by 365 basis points to 22.1%, and net profit fell by 9% year-on-year. This decline was attributed to costs associated with the opening of new facilities, as the company added approximately 320 beds during the quarter. Aggressive Expansion Fuels Future Growth KIMS's future growth is expected to be driven by its aggressive expansion strategy. The company is actively building its presence in new markets while its recent ventures are showing promising results. → Project Pipeline and New Facilities: New facilities in Kerala are performing well, with the Kannur unit turning EBITDA positive in Q1. The Kollam unit is expected to follow suit in Q2. The company launched three new hospitals in Q1: two in Bengaluru and one in Thane (Mumbai). These new units are expected to initially impact margins in FY26 as they operate at partial capacity and work on empanelment with insurance networks. → Long-Term Outlook: KIMS is on track to add approximately 2,300 beds by FY27, which will increase its total bed capacity by 42% to roughly 7,800 beds. This expansion will be a mix of brownfield and greenfield projects across Tier 1 and Tier 2/3 cities, positioning KIMS as a stronger player in the healthcare space in the coming years.